• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by MDxHealth SA

    7/2/26 4:15:17 PM ET
    $MDXH
    Medical Specialities
    Health Care
    Get the next $MDXH alert in real time by email
    6-K 1 ea0296595-6k_mdxhealth.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2026

     

    Commission File Number 001-40996

     

    MDXHEALTH SA

    (Translation of registrant’s name into English)

     

    CAP Business Center

    Zone Industrielle des Hauts-Sarts

    4040 Herstal, Belgium

    +32 4 257 70 21

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒    Form 40-F ☐

     

     

     

     

    MDXHEALTH SA

     

    On June 30, 2026, MDxHealth SA (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s ordinary shares has fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).

     

    The Notice has no immediate effect on the listing of the Company’s ordinary shares on The Nasdaq Capital Market and does not affect the Company’s reporting requirements with the Securities and Exchange Commission. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with a compliance period of 180 calendar days, or until December 28, 2026, to regain compliance with the Bid Price Requirement (the “Initial Compliance Period”). To regain compliance, the closing bid price of the Company’s ordinary shares must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior to December 28, 2026.

     

    If the Company does not regain compliance by December 28, 2026, the Company may be eligible for an additional grace period. To qualify, the Company must, as of the final day of the Initial Compliance Period, meet the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on the Capital Market (except the bid price requirement) based on the Company’s most recent public filings and market information and must notify Nasdaq of its intent to cure this deficiency. If the Company meets these requirements, the Nasdaq staff would be expected to grant an additional 180 calendar days for the Company to regain compliance with Bid Price Requirement.

     

    The Company is currently evaluating various courses of action to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will regain compliance with the Bid Price Requirement during the Initial Compliance Period, secure an extension of the compliance period beyond December 28, 2026 or maintain compliance with any other Nasdaq listing requirement.

     

    Additionally, on July 2, 2026, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1.

     

    Forward-Looking Statements

     

    This Report of Foreign Private Issuer on Form 6-K contains certain forward-looking statements within the meaning of federal securities laws with respect to the Company. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: our ability to cure any deficiencies in compliance with the Bid Price Requirement or maintain compliance with other Nasdaq Listing Rules; our eligibility for additional compliance periods, if necessary, in which to seek to regain compliance with the Bid Price Requirement; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or to meet applicable Nasdaq requirements for any such relief or extension; and risks related to the substantial costs and diversion of personnel’s attention and resources due to these matters. While we are planning to take actions to address non-compliance with the Bid Price Requirement, and have at least 180 days to do so, there can be no assurance that compliance will be achieved. Such non-compliance or a delisting from Nasdaq would materially and adversely affect our ability to raise capital and our financial condition and business. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

     

    Incorporation by Reference

     

    This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-280606 and File No. 333-292463) and Form S-8 (File No. 333-294873), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

     

    Exhibit No.   Description of Exhibit
    99.1   Press Release, dated July 2, 2026

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      MDXHEALTH SA
         
    Date: July 2, 2026 By: /s/ Michael McGarrity
        Name:  Michael McGarrity
        Title: Chief Executive Officer

     

    2

     

    Get the next $MDXH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXH

    DatePrice TargetRatingAnalyst
    5/14/2026Outperform → Mkt Perform
    William Blair
    7/17/2025$8.00Buy
    Craig Hallum
    10/31/2024$7.00Buy
    Lake Street
    5/31/2023$7.00Outperform
    TD Cowen
    7/18/2022$18.00Outperform
    Oppenheimer
    More analyst ratings

    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MDxHealth SA downgraded by William Blair

    William Blair downgraded MDxHealth SA from Outperform to Mkt Perform

    5/14/26 9:46:27 AM ET
    $MDXH
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on MDxHealth SA with a new price target

    Craig Hallum initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $8.00

    7/17/25 9:10:18 AM ET
    $MDXH
    Medical Specialities
    Health Care

    Lake Street initiated coverage on MDxHealth SA with a new price target

    Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

    10/31/24 8:59:17 AM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification. Na

    7/2/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

    Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world’s leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.

    6/29/26 8:00:00 AM ET
    $MDXH
    Medical Specialities
    Health Care

    Mdxhealth Reports Q1-2026 Results

    Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026. Michael K. McGarrity, CEO of mdxhealth, commented: "As we prioritized the integration of our recently acquired ExoDx business and to allow for renewed focus on our core prostate cancer business, we have made the strategic decision to discontinue our Resolve UTI offering and laboratory operations in Plano, Texas. The Resolve test was uniquely designed for our urology cus

    5/13/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA

    SCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)

    7/8/26 3:58:13 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form 6-K filed by MDxHealth SA

    6-K - MDxHealth SA (0001872529) (Filer)

    7/2/26 4:15:17 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form 6-K filed by MDxHealth SA

    6-K - MDxHealth SA (0001872529) (Filer)

    5/13/26 4:21:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Sollee Joseph

    4 - MDxHealth SA (0001872529) (Issuer)

    6/3/26 5:30:19 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Hardison Don M

    4 - MDxHealth SA (0001872529) (Issuer)

    6/3/26 5:30:16 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Chief Executive Officer Mcgarrity Michael

    4 - MDxHealth SA (0001872529) (Issuer)

    6/3/26 5:30:11 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    Leadership Updates

    Live Leadership Updates

    View All

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

    7/8/24 8:00:00 AM ET
    $MDXH
    Medical Specialities
    Health Care

    Mdxhealth Announces Resignation of Board Member

    Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor

    2/16/24 8:45:00 AM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MDxHealth SA

    SC 13G - MDxHealth SA (0001872529) (Subject)

    11/14/24 3:15:43 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by MDxHealth SA

    SC 13D/A - MDxHealth SA (0001872529) (Subject)

    10/28/24 2:52:50 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MDxHealth SA

    SC 13G - MDxHealth SA (0001872529) (Subject)

    10/4/24 5:14:19 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $MDXH
    Financials

    Live finance-specific insights

    View All

    Mdxhealth Reports Q1-2026 Results

    Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026. Michael K. McGarrity, CEO of mdxhealth, commented: "As we prioritized the integration of our recently acquired ExoDx business and to allow for renewed focus on our core prostate cancer business, we have made the strategic decision to discontinue our Resolve UTI offering and laboratory operations in Plano, Texas. The Resolve test was uniquely designed for our urology cus

    5/13/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Mdxhealth to Release First Quarter 2026 Financial Results on May 13

    Mdxhealth to Release First Quarter 2026 Financial Results on May 13 Company to Host Conference Call with Live Q&A, May 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2026, after market close on Wednesday, May 13, 2026. Title:Mdxhealth Presents First Quarter 2026 Financial Results andCorporate Update Conference Call and WebcastDate:May 13, 2026Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-800-245-3047Belgium: 0800 72 519United Kingdom: 0808 101 1183Conference ID: 

    4/30/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consiste

    2/26/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care